Stereoselectivity is the preferential formation of one stereoisomer over another in a chemical reaction. When a reaction could potentially produce multiple products that have the same atoms and bonds but differ in their three-dimensional arrangement, a stereoselective reaction favors one of those arrangements. The preference can be slight or nearly absolute, and controlling it is one of the central challenges in modern chemistry, particularly in drug development.
How Stereoselectivity Works
Molecules with the same chemical formula and bonding pattern can exist in mirror-image forms or other spatial arrangements called stereoisomers. Think of your left and right hands: identical in composition, but not superimposable. When a chemical reaction creates a new three-dimensional center in a molecule, it can often produce two or more of these spatial arrangements. Stereoselectivity describes how strongly the reaction favors one arrangement over the others.
The preference comes down to energy. Every reaction passes through a high-energy transition state, a fleeting molecular arrangement between starting material and product. When the transition state leading to one stereoisomer is lower in energy than the transition state leading to another, the lower-energy path is followed more often. Even small energy differences of a few kilocalories per mole can push a reaction heavily toward one product. Factors like the size and shape of the groups around the reaction site, the presence of a catalyst, temperature, and solvent all influence which transition state wins.
An important related concept is the Curtin-Hammett Principle: the ratio of products from a set of rapidly interconverting molecular shapes is determined by the energies of the transition states, not by how much of each shape is present at any given moment. This means you can’t predict selectivity just by looking at which starting arrangement is most stable. You have to consider the barriers each arrangement must cross.
Stereoselectivity vs. Stereospecificity
These two terms are often confused, but the distinction matters. A stereoselective reaction starts from a single reactant that could give multiple stereoisomeric products and preferentially gives one. A stereospecific reaction is a stricter case: each stereoisomer of the starting material maps cleanly onto a distinct stereoisomer of the product. Change the starting geometry, and you get a different product geometry every time.
Every stereospecific reaction is inherently stereoselective, but the reverse isn’t true. A reaction can favor one product without perfectly tracking the geometry of the starting material.
Types of Stereoselectivity
When the favored and disfavored products are mirror images of each other (enantiomers), the preference is called enantioselectivity. When they differ in other spatial ways (diastereomers), it’s called diastereoselectivity. These categories matter because they’re measured differently and controlled by different strategies.
Enantioselectivity is traditionally quantified using enantiomeric excess (ee), which expresses how much one mirror-image form dominates the mixture. If a reaction produces 95% of one enantiomer and 5% of the other, the ee is 90%. Some chemists now prefer reporting the enantiomeric ratio (er) directly, such as 95:5, because it more transparently reflects the actual composition. The same logic applies to diastereomeric excess (de) versus diastereomeric ratio (dr).
Predicting Which Product Forms
Chemists have developed several models to predict stereoselectivity in common reaction types. For additions to carbon-oxygen double bonds next to a chiral center, the Felkin-Anh model is the standard starting point. It predicts which face of the double bond a reagent will attack based on how the surrounding groups arrange themselves to minimize crowding. The incoming reagent approaches along a specific angle known as the Bürgi-Dunitz trajectory, aimed at the empty antibonding orbital of the double bond.
When a nearby oxygen, nitrogen, or sulfur atom can coordinate with a metal in the reagent, a cyclic chelated structure forms that locks the molecule into a particular shape. This “chelation effect,” first recognized by Donald Cram, often reverses the selectivity predicted by the standard Felkin-Anh model. Large reagents tend to restore Felkin-Anh selectivity because the chelated arrangement becomes too sterically crowded.
These models are approximations. Real molecules are flexible, and the interplay between steric bulk, electronic effects, and metal coordination makes prediction part science, part pattern recognition.
Controlling Selectivity With Catalysts
The most powerful approach to achieving high stereoselectivity is asymmetric catalysis: using a small amount of a chiral catalyst to steer the reaction toward one product. The catalyst creates a chiral environment around the reaction site, making the transition state leading to one stereoisomer significantly more favorable than the other.
Metal-based asymmetric catalysis traces back to efforts in the 1950s to achieve asymmetric hydrogenation. The discovery in 1966 that a rhodium complex could catalyze hydrogenation set the stage. Replacing the standard ligands on the metal with chiral versions was a conceptually straightforward leap that opened up enormous practical possibilities. The catalyst differentiates the two faces of a flat, symmetric functional group (like a carbon-carbon double bond) so that a new bond forms preferentially from one side.
Enzymes are nature’s version of asymmetric catalysts, and purified enzymes like lipases remain widely used in industry because they often deliver near-perfect selectivity under mild conditions. On the synthetic side, organocatalysis (using small organic molecules instead of metals) has become a major field. In 2024 and 2025, researchers reported organocatalytic methods achieving selectivity factors above 300 and enantiomeric excesses up to 99%, demonstrating that these metal-free approaches can rival traditional methods in precision.
External Factors That Shift Selectivity
Temperature and solvent choice can dramatically alter stereochemical outcomes. Lowering the temperature generally increases selectivity because it amplifies the energy difference between competing transition states. Small energy gaps that barely matter at room temperature become decisive when thermal energy is reduced. In one well-studied system involving oxygen-based reactions, cooling from room temperature to minus 70°C in methanol transformed a modestly selective reaction into an effective resolution of mirror-image compounds.
Solvent polarity matters because it changes how well charges and dipoles are stabilized in the transition state. A polar solvent can stabilize one transition state geometry more than another, flipping or enhancing selectivity. Chemists routinely screen solvents and temperatures as part of optimizing a stereoselective reaction.
Why It Matters for Medicines
Stereoselectivity has life-or-death relevance in pharmaceuticals. Mirror-image forms of the same drug molecule interact differently with the body’s enzymes and receptors, which are themselves chiral. One enantiomer may treat a disease while its mirror image has a completely different effect, or is even toxic.
The most infamous example is thalidomide. The (R)-enantiomer acts as a sedative, while the (S)-enantiomer causes severe birth defects. Studies in zebrafish confirmed that the (S)-form induces significantly greater developmental damage. Making matters worse, the two forms interconvert in the body, so administering only the “safe” enantiomer doesn’t fully solve the problem.
A more routine example is omeprazole, a common acid reflux medication. Its (S)-enantiomer, sold as esomeprazole, demonstrates significantly greater efficacy than the mixed-enantiomer version while maintaining comparable safety. This happens because the two enantiomers are broken down at different rates by liver enzymes, leading to different amounts of active drug reaching the bloodstream.
These differences extend broadly across chiral drugs. Enantiomers typically bind differently to the enzymes that metabolize them, producing different breakdown products at different rates. This means two mirror-image forms of the same molecule can have different effective doses, different durations of action, and different side effect profiles. They can even trigger different drug interactions when taken alongside other medications.
How Regulators Handle Chirality
The FDA requires that drug developers know the stereoisomeric composition of any chiral drug and characterize each enantiomer’s pharmacological activity, potency, and specificity separately. Pharmacokinetic studies must use assays that can distinguish individual enantiomers, because tests that lump them together will produce misleading results if the body handles them differently.
Manufacturing processes must include stereochemically specific identity tests and assay methods, and stability protocols must verify that the drug maintains its intended stereochemical composition over time. Labels must include appropriate stereochemical descriptors in the chemical name. A racemic mixture (equal parts of both enantiomers) is only acceptable if there’s no meaningful difference in efficacy or toxicity between the two forms. Because of these requirements, the majority of newly approved chiral drugs are now developed as single enantiomers rather than mixtures, reflecting a broader shift toward precision in drug design.